DAPK1 showed an inverse correlation between promoter methylation and gene expression consistent with epigenetic gene regulation ( Figure 2a , Table 1 ). The predictive value for true DAPK1 methylation was 1.0, sensitivity 0.86 and accuracy of the classifier 0.95. T-ALL cell lines on an average showed more than 100-fold higher DAPK1 expression levels than did NK, NK/T-and T-cell lymphoma cell lines (Figure 2b ). Western blot analysis confirmed cell type-specific DAPK1 expression also on the protein level ( Figure 2c , Table 1 ).
A 60-year-old male was examined for a prolonged history of dyspepsia. Gastroscopy showed moderate chronic duodenitis. Computed tomography imaging of the abdomen revealed central mesenteric lymphadenopathy (subcentimeter) with associated mesenteric fat stranding. Laparoscopic biopsy of the mesenteric lymph node was undertaken.
The lymph node parenchyma predominantly contained lymphoid follicles with preserved mantle zones and germinal centers. A few follicles, by contrast, lacked well-defined germinal centers and contained a monotonous population of small lymphoid cells and no tingible body macrophages. The interfollicular areas featured a mixed population of small lymphocytes, histiocytes and small clusters of plasma cells. Immunohistochemistry studies showed that the majority of follicles were negative for bcl-2. However, the few follicles with monotonous small cells showed strongly positive staining for bcl-2, CD20, CD10 and bcl-6 ( Figure 1 ). In addition, the majority of the interfollicular plasma cells were positive for bcl-2, k light chain, IgG and negative for l light chain and CD10.
The presence of a BCL-2/IGH fusion gene was demonstrated by both fluorescence in situ hybridization and PCR. DNA for PCR analysis was extracted from sections of the intact lymph node tissue (microdissection was not available). Additional PCR studies showed monoclonal rearrangement of the IGH gene. Overall, the combined morphologic and immunophenotypic features were consistent with ISLFL.
Polymerase chain reaction testing was also carried out on peripheral blood mononuclear cells. DNA was extracted as described earlier, and amplification for the BCL-2/ IGH translocation was performed in triplicate with primers for the BCL-2 major breakpoint region (MBR) and joining region (JH) consensus primers using SYBR Green I (QuantiTect, QIAGEN, Mississauga, ON, Canada) for real-time quantitative PCR.
1 PCR product from this reaction was quantified as amplifying from approximately 0.01% of the peripheral blood cells. Amplification using primers for the RAG2 gene served as a control for amplifiable DNA quantity. 1 The PCR test was then repeated on the DNA extracted earlier from the sections of the intact lymph node. The BCL-2/IGH fusion gene was detected in high copy numbers in the lymph node DNA. Through visualization on a 3% agarose gel, both the peripheral blood and the lymph node PCR products were identical in size at approximately 300bp ( Figure 2 ). DNA sequencing confirmed that both the PCR products were identical and revealed a junction of the MBR region of the BCL-2 gene to JH6 of the IGH gene with 20 nucleotides of intervening sequence.
The patient continues to do well without any clinical or radiologic features of progression 2 years following his biopsy. Bone marrow biopsy and colonoscopy were declined. Careful observation and long-term follow-up have been recommended. Follicular lymphoma is the second most common subtype of non-Hodgkin's lymphoma, and the prototypical indolent lymphoma. 2 FL is characterized by the translocation t(14;18)(q32;q21), which places the expression of the BCL-2 proto-oncogene on chromosome 18 under the control of the IGH gene locus on chromosome 14. 3 The resultant overexpression of the bcl-2 protein is associated with inhibition of apoptosis and the accumulation of follicular center B-cells that otherwise would have undergone programmed cell death. 4 The detection of bcl-2 protein expression by immunohistochemistry is valuable for distinguishing between the malignant lymphoid follicles of FL and benign follicular hyperplasia, which would not show staining for bcl-2.
Recently, a series of 23 lymph node biopsies was identified, in which focal germinal centers contained small cells that showed intensely strong staining for bcl-2, but the remaining lymphoid tissue showed follicular hyperplasia that was bcl-2 negative. 5 The designation of ISLFL was proposed for the affected follicles. In some of these cases, laser capture microdissection of individual follicles followed by PCR analyses showed the presence of monoclonal IGH gene rearrangements and BCL-2/IGH rearrangements only in the bcl-2 positive follicles. Follow-up of this cohort has shown variable clinical significance of ISLFL, with some patients found to have synchronous FL at other sites at presentation, others developing subsequent lymphoma, usually FL, with further follow-up, and another group that never progressed to FL (over follow-up ranging from 2 to 96 months). The cases suggest that ISLFL may represent either a preneoplastic event or an early stage of FL. We report a case that meets the pathologic definition of ISLFL. Further search for occult systemic disease with PCR revealed the presence of the identical BCL-2/IGH gene rearrangement in peripheral blood to that found in the lymph node specimen. This is the first report of disseminated ISLFL disease, as shown by molecular diagnostic criteria, and supports the hypothesis that systemic involvement by ISLFL precedes the homing of malignant cells to reactive germinal centers. The t(14;18) translocation that underlies both ISLFL and FL is believed to occur during the antigen-independent stages of B-cell development. 5 The translocation may result from errors in V-to-DJ rearrangement at the pre-B-cell stage of differentiation in the bone marrow. 6, 7 Analogous to its normal counterpart, the bone marrow-derived B-cell with the t(14;18) translocation is then believed to migrate to lymphoid follicles in the lymph nodes. The detection of ISLFL may represent the initial seeding of reactive germinal centers by monoclonal B-cells. Subsequent development of FL would still warrant additional mutations that result in the expression of malignant behavior. 6 However, the suggestion that ISLFL may represent an isolated or limited preneoplastic process is less favored in view of the demonstration of a quantifiable systemic clonogenic B-cell population.
We appreciate that the BCL-2/IGH gene rearrangement can be detected in the peripheral blood of normal individuals without clinical evidence of lymphoma. 8, 9 The presence of the identical gene rearrangement within the lymph node and the peripheral blood in this case, however, is more in keeping with the hypothesis that these clinical pathologic entities represent potentially sequential stages in the molecular and cellular pathogenesis leading to FL. 10 Alternatively, the circulating t(14;18) positive B-cells may represent the detection of FL-like, but pre-malignant, B-cells known to intensely traffic between follicles. 11 Still, the peripheral blood findings may represent evidence of B-cell trafficking and not indicate progression to FL. 11 Immunohistochemical examination of the lymph node also showed the presence of a small, but distinct, population of bcl-2 positive, monoclonal (k-staining) plasma cells. These clusters of cells in the interfollicular areas may represent plasma-cell differentiation of the same clone as the in-situ FL cells or an independent clonal proliferation. The composite presence of in situ FL and another low-grade B-cell lymphoproliferative disorder was earlier reported in two additional cases of ISLFL. 5 As in our case, microdissection to distinguish the clonal relationship of the two processes was unavailable, the clinical significance of these presentations is currently unknown.
We report a case of ISLFL in which there is quantifiable molecular evidence of systemic involvement. The findings suggest that ISLFL represents an early and subclinical presentation of FL, and that systemic disease accompanies the homing of FL cells to lymphoid follicles. Although systemic disease may be present, the relationship of this to the prognosis and the development of clinically apparent or symptomatic disease is unknown. Consequently, it is still suggested that expectant observation is the appropriate clinical management for a finding of ISLFL. 
Letters to the Editor
The t(7;12) rearrangement involving ETV6 has been found in Bone-third of acute myeloid leukaemia in early childhood.
1,2 In a proportion of these cases, the homeobox gene HLXB9 has been identified as the fusion partner at the transcript level. 3 In this study, we analyzed 10 paediatric patients with acute myeloid leukaemia. Of these, seven (patient nos. 1-7) carried a t(7;12)(q36;p13), whereas three patients (nos. 8-10) were used as controls as they lacked abnormalities of either chromosome 7 or 12 (see Table 1 ). Expression analysis was carried out on all patients to investigate the presence of the specific transcripts ETV6, HLXB9, NOM1, the HLXB9-ETV6 fusion and its reciprocal ETV6-HLXB9. Furthermore, all patients were studied for the presence of a possible NOM1-ETV6 fusion (for primers, see Supplementary Material). The expression data obtained by RT-PCR are reported in Figure 1 . The ETV6 gene was expressed in all patients (data not shown). The HLXB9 gene was expressed in all seven patients with the t(7;12) (patients nos. 1-7) and in one of the three patients without the t(7;12) (patient no. 10, Figure 1e ). The fusion transcript HLXB9-ETV6 was detected in four out of seven patients with the t(7;12) (patient nos. 1, 2, 5 and 7) and in none of the patients without the t(7;12) (patients nos. 8-10, Figures 1a and b) . There was no evidence for the presence of the reciprocal transcript ETV6-HLXB9 in any patient. The NOM1 gene was expressed in two t(7;12) patients (case nos. 1 and 2) and in one case without the t(7;12) (patient no. 10, Figure 1f ). There was no evidence for the presence of a possible fusion transcript NOM1-ETV6 in any of the analyzed patients.
A growing number of studies indicate that the higher-order chromatin arrangement is related to gene expression. 6 Alterations of the nuclear architecture, including localization and compaction of large DNA regions, their replication timing and the relative expression levels are emerging factors in human diseases, including cancer. 7 The aim of this study was to investigate whether the altered expression pattern of the HLXB9 gene would correspond to an altered radial nuclear location of the 7q36 fragment (containing HLXB9) translocated on the der(12). We designed a fluorescence in situ hybridization assay that uses combinations of probes specific for the 7q36 and 12p13 regions, and can differentiate the derivative chromosomes from the wild-type homologues in the interphase nuclei (see Figure 2) . Table 1 Clinical and cytogenetic data of the patients analyzed in this study 
